Clinical Trial Update: Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2 and Phase 3 clinical trials evaluated progesterone 17-hydroxyprogesterone caproate (Makena) for prolonging pregnancy in women with preterm rupture of me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Preterm Birth

Drugs mentioned

• Makena (hydroxyprogesterone caproate)

Snippet

Sponsor: Obstetrix Medical Group | Conditions: Preterm Delivery | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2018-05-30